Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Capvaxive by Year
Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — U.S. sales ($M) ($M)
Merck Capvaxive: $730M in FY2025, up 660.4% from a year earlier.
Latest, FY2025
730
Period ended Dec 31, 2025
Change on a year earlier
+660.4%
96 in FY2024
History
3 years
Since FY2023
Sources
2
Documents cited below
Where the FY2025 figure comes from
“|| Capvaxive | 759 | 97 | * | 730 | 96 | * | 29 | 1 | *”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 730 | +660.4% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 96 | – | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 0 | – | Form 10-K (filed 2026-02-24) ↗ |
Cite this data
StockData. (2026). Merck Capvaxive ($M), annual FY2023–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-capvaxive-us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.